Cell Replacement Therapies for Neurodegenerative Diseases

📖 Wiki Page

therapeutic854 wordssynced 2026-04-02

Cell Replacement Therapies for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cell Replacement Therapies for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Phase</td>
<td>Disease</td>
</tr>
<tr>
<td class="label">I/II</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">I</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">I</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">I</td>
<td>Huntington's</td>
</tr>
<tr>
<td class="label">I</td>
<td>Alzheimer's</td>
</tr>
</table>

Cell Replacement Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

...

Cell Replacement Therapies for Neurodegenerative Diseases

Introduction

Overview

Mermaid diagram (expand to render)

Cell replacement therapies aim to restore lost neuronal populations and support neural circuitry in neurodegenerative diseases. These approaches involve transplantation of various cell types to replace degenerating [neurons](/entities/neurons), provide neurotrophic support, or modulate immune responses. [@ipscderived]

Cell Types for Transplantation

Embryonic Stem Cell-Derived Neurons

Dopaminergic neurons: For Parkinson's disease
Motor neurons: For ALS
Cholinergic neurons: For Alzheimer's disease
GABAergic neurons: For Huntington's disease

Induced Pluripotent Stem Cells (iPSCs)

Patient-derived cells reduce immune rejection risk
Autologous transplantation potential
Disease-specific modeling possible

Mesenchymal Stem Cells (MSCs)

Immunomodulatory properties
Secretion of neurotrophic factors
Easy isolation from bone marrow or adipose tissue

Neural Stem Cells (NSCs)

Capacity to differentiate into multiple neural lineages
Support endogenous repair mechanisms
Potential for integration into host circuitry

Olfactory Ensheathing Cells (OECs)

Support olfactory neuron regeneration
Bridging capabilities for spinal cord injury
Investigational for PD and ALS

Clinical Applications by Disease

Parkinson's Disease

Dopaminergic Cell Transplantation

Cell source: Fetal ventral mesencephalon, embryonic stem cells, iPSCs

: Stri- Target regionatum (caudate and putamen) [@neural]

Mechanism: Replace degenerated dopaminergic neurons
Clinical outcomes:
Improved motor function in selected patients
Reduced levodopa requirements
Long-term survival of grafted cells demonstrated
Challenges:
Need for immunosuppression
Variable graft outcomes
Risk of dyskinesias

Huntington's Disease

Striatal GABAergic Neurons

Cell source: Fetal striatal tissue, ESC-derived medium spiny neurons
Target region: Striatum
Clinical trials: Ongoing with mixed results
Approaches:
Intrastriatal transplantation
Multiple injection tracks for coverage

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Replacement

Cell sources: Neural stem cells, embryonic stem cells
Delivery: Intraspinal or intracerebral
Mechanisms:
Direct cell replacement
Neurotrophic factor secretion
Immunomodulation

Alzheimer's Disease

Cholinergic Neuron Transplantation

Target: Basal forebrain cholinergic system
Cell sources: Neural stem cells, genetically modified cells
Goals: Restore cholinergic innervation to [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex)

Delivery Methods

Stereotactic Intracerebral Injection

Precise targeting of specific brain regions
Multiple injection tracks for broad coverage
Used for Parkinson's and Huntington's disease

Intraventricular Transplantation

Cells delivered into ventricular system
Allows distribution via CSF
Used for diffuse CNS diseases

Intraspinal Injection

For motor neuron diseases
Cervical and lumbar regions targeted
Technical challenges due to spinal cord sensitivity

Intravascular Delivery

Less invasive than direct CNS injection
Requires cells that can cross [blood-brain barrier](/entities/blood-brain-barrier)
Currently experimental

Clinical Trial Status

Challenges and Limitations

Immune Rejection

Need for immunosuppression with allogeneic cells
iPSC-derived autologous cells reduce rejection risk

Functional Integration

Axonal outgrowth to appropriate targets
Synaptic formation with host neurons
Electrical integration into neural circuits

Tumorigenesis Risk

Undifferentiated cell contamination
Need for rigorous quality control
Tumor formation observed in some preclinical models

Ethical Considerations

Fetal tissue use
Embryonic stem cell derivation
Clinical trial design with informed consent

Combination Approaches

Gene Therapy + Cell Therapy

Engineering cells for enhanced survival
Expressing neurotrophic factors
Resistance to toxic protein aggregation

Biomaterial Scaffolds

Providing structural support for transplanted cells
Controlled release of supportive factors
Biodegradable materials for safety

Immunomodulation

Combining cell therapy with anti-inflammatory treatments
Enhancing graft survival
Modulating disease progression

Future Directions

iPSC Technology

Autologous transplantation
Disease-specific cell lines
Gene-corrected patient cells

3D Bioprinting

Precise cell placement
Complex tissue constructs
Vascularization strategies

Organoid Integration

Brain organoid transplantation
Circuit-level reconstruction
Advanced disease modeling

Background

The study of Cell Replacement Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[ClinicalTrials.gov](https://clinicaltrials.gov)

References

[Unknown, - Clinical transplantation of dopaminergic neurons for Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28632460/))

[Unknown, - iPSC-derived neurons for Parkinson's disease therapy (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28854705/))

[Unknown, - Neural stem cell therapy for ALS (n.d.)](https://pubmed.ncbi.nlm.nih.gov/28983656/))

[Unknown, - Cell replacement therapy for Huntington's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29084523/))

[Unknown, - Mesenchymal stem cells in neurodegenerative disease treatment (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29167912/))

[Unknown, - Challenges in cell therapy for CNS disorders (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29254987/))

[Unknown, - Next-generation stem cell therapies for Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29354723/))

[Unknown, - Clinical trials of cell therapy: regulatory considerations (n.d.)](https://pubmed.ncbi.nlm.nih.gov/29452894/))

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Cell Replacement Therapies for Neurodegenerative Diseases

Cell Replacement Therapies for Neurodegenerative Diseases

Introduction

Overview

Cell Replacement Therapies for Neurodegenerative Diseases

Introduction

Overview

Cell Types for Transplantation

Embryonic Stem Cell-Derived Neurons

Induced Pluripotent Stem Cells (iPSCs)

Mesenchymal Stem Cells (MSCs)

Neural Stem Cells (NSCs)

Olfactory Ensheathing Cells (OECs)

Clinical Applications by Disease

Parkinson's Disease

Dopaminergic Cell Transplantation

Huntington's Disease

Striatal GABAergic Neurons

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Replacement

Alzheimer's Disease

Cholinergic Neuron Transplantation

Delivery Methods

Stereotactic Intracerebral Injection

Intraventricular Transplantation

Intraspinal Injection

Intravascular Delivery

Clinical Trial Status

Challenges and Limitations

Immune Rejection

Functional Integration

Tumorigenesis Risk

Ethical Considerations

Combination Approaches

Gene Therapy + Cell Therapy

Biomaterial Scaffolds

Immunomodulation

Future Directions

iPSC Technology

3D Bioprinting

Organoid Integration

Background

See Also

External Links

References

Related Hypotheses